<!--[if (gte mso 9)|(IE)]>
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]-->
<!--[if (gte mso 9)|(IE)]>
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]-->
<!--[if (gte mso 9)|(IE)]>
<![endif]--> <!--[if (gte mso 9)|(IE)]>
| <![endif]-->
<!--[if (gte mso 9)|(IE)]> |
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]--> |
<!--[if (gte mso 9)|(IE)]> |
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]-->
<!--[if (gte mso 9)|(IE)]>
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]-->
|
Bridgewater, NJ, Alembic Pharmaceuticals, Inc is voluntarily recalling one lot of Telmisartan Tablets, USP, 20 mg, packaged in 30-count bottles, Lot No. 1905005661 to the consumer level. The product is being recalled due to a market complaint received which stated that one bottle labelled as 30-count Telmisartan Tablets, USP, 20 mg incorrectly contained 30 tablets of Telmisartan Tablets, USP, 40mg.
Risk Statement: Patients who could be on a doubled dose of telmisartan for a prolonged period of time, could experience low blood pressure, worsening of kidney function, or an elevation of potassium which can be life-threatening. To date, Alembic Pharmaceuticals Limited has not received any reports of adverse events related to this recall.
The product is used for the treatment of hypertension i.e. to lower blood pressure and is packaged in a bottle of 30 tablets having NDC Number 62332-087-30. The affected lot of Telmisartan Tablets, USP, 20 mg is the lot number 1905005661 and the lot expires in March 2022.Â
|
<!--[if (gte mso 9)|(IE)]> |
<![endif]--> <!--[if (gte mso 9)|(IE)]>
<![endif]--> |
<!--[if (gte mso 9)|(IE)]> |
<![endif]-->
|
